Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

I last wrote about Organon (NYSE: OGN ) back in June , prior to its second-quarter 2025 results, and since then, the company's stock has moved nowhere but sideways. The results presented for the second quarter were slightlyI am a value focused investor, conducting fundamental research on sectors like but not limited to chemicals, homebuilders, building materials, industrials and metals & mining. I prefer to invest in stocks which are cheaply available and have a catalyst in the near future. My investment ho ...